On Tuesday, Profarma announced that it has signed a contract to purchase the entirety of 4Bio Medicamentos from RD Saúde, which includes the brands Raia and Drogasil, for a total of R$ 600 million. This amount includes the maintenance of a liquid cash holding of R$ 80 million in the company at the closure of the operation, and is subject to price adjustments based on 4Bio's net indebtedness and/or working capital, as per relevant facts released. The payment schedule outlines an immediate R$ 100 million payment at closing, followed by five annual installments of R$ 100 million each, adjusted by a rate of 100% of the CDI accumulated from the closing date to the effective date of each payment.

4Bio, founded in 2004, operates in the institutional segment, primarily focusing on the sale of special and high-complexity medications for patients, health professionals, clinics, hospitals, and health plan operators. Notably, RD Saúde acquired control of 4Bio in 2015, indicating a longer-term strategic relationship before this recent sale. This acquisition positions Profarma to expand its footprint in the pharmaceutical sector, particularly in high-complexity pharmaceuticals, which could have significant ramifications for market competition and supply chain dynamics within Brazil's healthcare system.